🇺🇸 FDA
Pipeline program

CM-336 BCMA/CD3 bispecific antibody

IIT2024012

Unknown small_molecule terminated

Quick answer

CM-336 BCMA/CD3 bispecific antibody for AL Amyloidosis is a Unknown program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
AL Amyloidosis
Phase
Unknown
Modality
small_molecule
Status
terminated

Clinical trials